N-1,2,3-Triazole-Isatin derivatives in lymphoma cell lines

Detalhes bibliográficos
Autor(a) principal: Gaudio, E.
Data de Publicação: 2022
Outros Autores: Tarantelli, C., Marques, C.S., Ekeh, H., Carmelo, M., Burke, A.J., Bertoni, F.
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10174/34964
https://doi.org/10.1016/S0959-8049(22)00976-5
Resumo: Molecular hybrid constructs are an interesting approach to merge individual pharmacophores with different mechanisms of action, potentially decreasing side effects. The 1,2,3-triazole unit is present in many bioactive compounds and it is characterized by its ability to be stable towards hydrolysis to increase the compounds lipophilicity. Hybrids containing this pharmacophore together with isatin and its analogues have shown a wide spectrum of potential therapeutic activities, also against cancer. Burke et al. have recently reported new N-1,2,3-triazole-isatin hybrids with in vitro anti- tumor activity in solid tumor cell lines (RSC Medicinal Chemistry 2022; EP3400938). Here, we present the in vitro anti-lymphoma activity and structure activity relationships (SAR) of 9 N-1,2,3-triazole-isatin hybrids.
id RCAP_097e8a61e490e357a58b204eacf2b7a3
oai_identifier_str oai:dspace.uevora.pt:10174/34964
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling N-1,2,3-Triazole-Isatin derivatives in lymphoma cell linescancerisatinMolecular hybrid constructs are an interesting approach to merge individual pharmacophores with different mechanisms of action, potentially decreasing side effects. The 1,2,3-triazole unit is present in many bioactive compounds and it is characterized by its ability to be stable towards hydrolysis to increase the compounds lipophilicity. Hybrids containing this pharmacophore together with isatin and its analogues have shown a wide spectrum of potential therapeutic activities, also against cancer. Burke et al. have recently reported new N-1,2,3-triazole-isatin hybrids with in vitro anti- tumor activity in solid tumor cell lines (RSC Medicinal Chemistry 2022; EP3400938). Here, we present the in vitro anti-lymphoma activity and structure activity relationships (SAR) of 9 N-1,2,3-triazole-isatin hybrids.European Journal of Cancer2023-05-04T11:00:27Z2023-05-042022-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10174/34964http://hdl.handle.net/10174/34964https://doi.org/10.1016/S0959-8049(22)00976-5porhttps://www.sciencedirect.com/science/article/pii/S0959804922009765?via%3Dihubndndcarolsmarq@uevora.ptndndndnd303Gaudio, E.Tarantelli, C.Marques, C.S.Ekeh, H.Carmelo, M.Burke, A.J.Bertoni, F.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-01-03T19:38:08Zoai:dspace.uevora.pt:10174/34964Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T01:23:29.628681Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv N-1,2,3-Triazole-Isatin derivatives in lymphoma cell lines
title N-1,2,3-Triazole-Isatin derivatives in lymphoma cell lines
spellingShingle N-1,2,3-Triazole-Isatin derivatives in lymphoma cell lines
Gaudio, E.
cancer
isatin
title_short N-1,2,3-Triazole-Isatin derivatives in lymphoma cell lines
title_full N-1,2,3-Triazole-Isatin derivatives in lymphoma cell lines
title_fullStr N-1,2,3-Triazole-Isatin derivatives in lymphoma cell lines
title_full_unstemmed N-1,2,3-Triazole-Isatin derivatives in lymphoma cell lines
title_sort N-1,2,3-Triazole-Isatin derivatives in lymphoma cell lines
author Gaudio, E.
author_facet Gaudio, E.
Tarantelli, C.
Marques, C.S.
Ekeh, H.
Carmelo, M.
Burke, A.J.
Bertoni, F.
author_role author
author2 Tarantelli, C.
Marques, C.S.
Ekeh, H.
Carmelo, M.
Burke, A.J.
Bertoni, F.
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Gaudio, E.
Tarantelli, C.
Marques, C.S.
Ekeh, H.
Carmelo, M.
Burke, A.J.
Bertoni, F.
dc.subject.por.fl_str_mv cancer
isatin
topic cancer
isatin
description Molecular hybrid constructs are an interesting approach to merge individual pharmacophores with different mechanisms of action, potentially decreasing side effects. The 1,2,3-triazole unit is present in many bioactive compounds and it is characterized by its ability to be stable towards hydrolysis to increase the compounds lipophilicity. Hybrids containing this pharmacophore together with isatin and its analogues have shown a wide spectrum of potential therapeutic activities, also against cancer. Burke et al. have recently reported new N-1,2,3-triazole-isatin hybrids with in vitro anti- tumor activity in solid tumor cell lines (RSC Medicinal Chemistry 2022; EP3400938). Here, we present the in vitro anti-lymphoma activity and structure activity relationships (SAR) of 9 N-1,2,3-triazole-isatin hybrids.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-01T00:00:00Z
2023-05-04T11:00:27Z
2023-05-04
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10174/34964
http://hdl.handle.net/10174/34964
https://doi.org/10.1016/S0959-8049(22)00976-5
url http://hdl.handle.net/10174/34964
https://doi.org/10.1016/S0959-8049(22)00976-5
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.sciencedirect.com/science/article/pii/S0959804922009765?via%3Dihub
nd
nd
carolsmarq@uevora.pt
nd
nd
nd
nd
303
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv European Journal of Cancer
publisher.none.fl_str_mv European Journal of Cancer
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136717110771712

Registros relacionados